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Summary
Objective: To present the baseline data of the international TuberOus SClerosis reg-
istry to increase disease Awareness (TOSCA) with emphasis on the characteristics of 
epilepsies associated with tuberous sclerosis complex (TSC).
Methods: Retrospective and prospective patients’ data on all aspects of TSC were 
collected from multiple countries worldwide. Epilepsy variables included seizure 
type, age at onset, type of treatment, and treatment outcomes and association with 
genotype, seizures control, and intellectual disability. As for noninterventional regis-
tries, the study protocol did not specify any particular clinical instruments, laboratory 
investigations, or intervention. Evaluations included those required for diagnosis and 
management following local best practice.
Results: Epilepsy was reported in 83.6% of patients (1852/2216) at baseline; 38.9% 
presented with infantile spasms and 67.5% with focal seizures. The mean age at diag-
nosis of infantile spasms was 0.4 year (median <1 year; range <1- 30 years) and at 
diagnosis of focal seizures was 2.7 years (median 1 year; range <1- 66 years). A total 
of 1469 patients (79.3%) were diagnosed with epilepsy <2 years. The rate of infantile 
spasms was higher in patients with a TSC2 mutation than in patients with a TSC1 mu-
tation (47.3% vs 23%). 𝛾-aminobutyric acid (GABA)ergic drugs were the most com-
mon treatment modality for both infantile spasms (78.7%) and focal seizures (65.5%). 
Infantile spasms and focal seizures were controlled in 76.3% and 58.2% of patients, 
respectively. Control of seizures was associated with lower rates of intellectual disa-
bility in both groups.
Significance: This registry reports the largest international cohort of patients with 
TSC. Findings confirmed the typical onset pattern of infantile spasms and other focal 
seizures in the first 2 years of life, and the high rates of infantile spasms in patients 
with TSC2 mutation. Our results underscored the occurrence of focal seizures at all 
ages, including an onset that preceded emergence of infantile spasms. Seizure control 
was shown to be associated with lower rates of intellectual disability but did not 
 preclude the presence of intellectual disability.
K E Y W O R D S
epilepsy, registry, TOSCA, tuberous sclerosis complex
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1 |  INTRODUCTION
Epilepsy is one of the most common neurologic symptoms in 
patients with tuberous sclerosis complex (TSC), with reported 
prevalence from 62% to 93%.1–3 It is also a significant cause 
of morbidity and mortality in patients with TSC.2,4 Epilepsy 
usually begins during the first months of life and in the major-
ity before the first year.5 Early onset epilepsy often presents 
as focal seizures initially and can precede, coexist with, or 
evolve into infantile spasms.5,6 However, patients with TSC 
can present with almost all seizure types such as tonic, atonic, 
or tonic- clonic seizures.6 There are several therapeutic op-
tions available for the treatment of focal seizures and infan-
tile spasms associated with TSC including antiepileptic drugs 
(AEDs), hormonal therapy, epilepsy surgery, ketogenic diet, 
and vagus nerve stimulation. However, about two- thirds of 
patients develop treatment refractory epilepsies, associated 
with increased rates of intellectual disability and other TSC- 
associated neuropsychiatric disorders (TAND).6,7
The natural history of epilepsy in TSC has been evalu-
ated in only a handful of studies.1,2,8,9 Most of these studies 
were retrospective in nature, reported a single- center cohort, 
and had relatively small sample size. Only one large cohort 
was reported by Jeong et al, who evaluated the natural history 
of epilepsy in a cohort of patients with TSC enrolled from 
the United States and Belgium (n = 1816; 81.8% had his-
tory of focal seizures and 49.2% had infantile spasms).2 The 
TuberOus SClerosis registry to increase disease Awareness 
(TOSCA) is an international study that enrolled patients from 
170 centers across 31 countries worldwide. The baseline core 
data of TOSCA provided understanding of the overall TSC 
manifestations. The study showed epilepsy in 83.5% of pa-
tients, subependymal giant cell astrocytoma in 24.4%, and 
renal angiomyolipomas in 47.2%.10 Herein we report baseline 
data from TOSCA with the aim of describing the characteris-
tics of epilepsy among this large cohort of patients with TSC.
2 |  METHODS
The methods of the TOSCA study have been described in de-
tail previously.11 In short, TOSCA is a multicenter, interna-
tional disease study designed to collect data, retrospectively 
and prospectively, on patients with TSC from several coun-
tries worldwide. Sites with specialists in managing one or 
more aspects of TSC (in children and adults) were included 
in the registry. Centers were dedicated mainly to epilepsy 
care but with almost 30% of patients (mainly adult) enrolled 
from other specialties as well.
The registry consists of a “core” section and 6 subsections 
(“petals”). In the “core” section, general information on pa-
tient background such as demographic data, family history, 
genotype, vital signs, prenatal history, clinical features of TSC 
across all organ systems, comorbidities, and rare manifesta-
tions were reported. Data were collected retrospectively and 
prospectively at baseline (first inclusion visit) and interim 
analysis was performed on this data collection. A prospective 
follow- up observation period was up to 5 years, with regular 
visits scheduled at a minimum interval of 1 year to ensure an 
ongoing data stream. These follow- up data were not included 
in this article. Subsections (“petals”) represent specific re-
search projects to record in- depth data related to specific 
disease manifestations. Given that this is an international non-
interventional study, evaluations included were those required 
for disease diagnosis and management according to the local 
best practice. The study protocol, therefore, did not specify any 
particular clinical instruments or laboratory investigations.
Patients of any age who fulfilled clinical criteria for TSC di-
agnosis were eligible if they had at least 1 documented visit for 
TSC within the previous 12 months or were newly diagnosed 
with TSC before participating in the registry. Variables were 
obtained on the basis of the most recent data collected during 
the last visit and included seizure type (focal seizures, infan-
tile spasms, other seizures), age at onset of epilepsy, type of 
epilepsy treatment (grouped as γ- aminobutyric acid (GABA)
ergics, hormonal therapy, ketogenic diet, fructose deriva-
tives, vagus nerve stimulator, mammalian target of rapamycin 
(mTOR) inhibitors, surgery, other modalities) and treatment 
outcome (eg, epilepsy resolved spontaneously, was controlled 
with treatment, or was not controlled with treatment). In addi-
tion, we compared the characteristics of epilepsy between the 
overall epilepsy cohort and those with epilepsy diagnosed be-
fore 2 years of age (early onset seizure group). The association 
between seizure type and genotype as well as between seizure 
control and intellectual ability was evaluated. Intellectual abil-
ity was evaluated by clinician or by formal neuropsychologi-
cal test and categorized as normal (IQ > 70), mild intellectual 
disability (ID) (IQ 51–70), moderate ID (IQ 36–50), severe ID 
(IQ 20- 35), and profound ID (IQ < 20).
All eligible patients enrolled in the TOSCA study were 
considered in the analysis. Continuous variables were 
Key Points
• Epilepsy was reported in 1852 patients (83.6%) at 
baseline; of these, there were focal seizures in 
67.5% and infantile spasms in 38.9% patients
• Epilepsy was diagnosed before 2 years of age in 
approximately 79% of patients
• The rate of infantile spasms was higher in patients 
with TSC2 mutation than in patients with TSC1 
mutation
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analyzed in terms of value (number of patients, mean, stan-
dard deviation, median, minimum and maximum), whereas 
categorical variables (eg, presence/absence of a condition or 
manifestation) were analyzed in terms of frequency distribu-
tion at baseline. Missing data were not imputed.
This study was designed, implemented, and reported in 
accordance with the Good Clinical Practice and the ethical 
principles specified in the Declaration of Helsinki.12 The 
protocol was approved by the local ethics committee at each 
center before patient enrollment.
3 |  RESULTS
3.1 | Demographics and clinical 
characteristics
As of September 30, 2015 (data cutoff date for the third in-
terim analysis), 2216 eligible patients from 170 sites across 
31 countries worldwide were enrolled in the TOSCA study 
(Table 1). The third interim analysis included baseline data 
for all the patients enrolled in the study.
Baseline patient demographics and clinical characteristics 
are summarized in Table 2. Baseline data were available for 
1154 female (52.1%) and 1,062 male (47.9%) patients; 806 pa-
tients (36.4%) were adult (>18 years) and 1410 (63.6%) were 
children or adolescents. The median age at consent was 13 years 
(range < 1- 71). The mean age at TSC diagnosis was 7.0 years 
(median age 1 year; range < 1- 69). Molecular testing for genetic 
mutations was performed for 1000 patients who met clinical 
criteria for TSC (45.1%). Of these, 638 patients (63.8%) had a 
TSC2 mutation, 191 patients (19.1%) had a TSC1 mutation, and 
6 patients (0.6%) had both TSC1 and TSC2 mutations. No fur-
ther molecular details were requested for this study. Of patients 
who had genetic molecular testing performed, no TSC mutation 
was identified in 144 patients (14.4%), whereas test results were 
not available for 9 patients (0.9%). Prenatal diagnosis of TSC 
was reported in 144 patients (6.5%) and 500 patients (22.6%) 
had relatives affected with TSC.
3.2 | Characterization of epilepsy
Epilepsy was reported at the baseline visit in 1852 patients 
(83.6%) (overall epilepsy cohort). In this overall epilepsy co-
hort, a history of focal seizures was reported in 1250 patients 
(67.5%) and infantile spasms in 720 patients (38.9%). The 
co- occurrence of focal seizures and epileptic spasms was re-
ported in 380 patients (20.5%; Table 3). Of these, epileptic 
spasms occurred before focal seizures in 242 patients (13.1%) 
and focal seizures occurred first in 63 patients (3.4%). In 
75 patients (4%), focal seizures and epileptic spasms were 
reported as starting concomitantly. The mean age at diag-
nosis of focal seizures was 2.7 years (median age 1 year; 
range < 1- 66 years), whereas mean age at diagnosis of spasms 
was 0.4 years (median age < 1 year; range < 1- 30 years). In 
691 patients (95.6%), infantile spasms were reported within 
the typical age range (before 2 years). In 22 patients (3%), it 
occurred between 2 and 5 years and in 10 patients (1.4%) at 
an older age. The differences in the occurrence rate and age 
at diagnosis of focal seizures and epileptic spasms (alone or 
in combination with other types) among patients with TSC1 
mutation and TSC2 mutation are shown in Table 4. Infantile 
spasms were more frequent in patients with a TSC2 mutation 
compared to those with a TSC1 mutation (47.3% vs 23%).
T A B L E  1  Patients enrolled from different countries in TOSCA 
(N = 2216)
Countries
Number of 
patients, n (%)
Europe
 France 228 (10.3)
 The Netherlands 224 (10.1)
 Germany 162 (7.3)
 Spain 119 (5.4)
 Belgium 110 (5.0)
 Italy 97 (4.4)
 Portugal 54 (2.4)
 Austria 52 (2.3)
 Poland 52 (2.3)
 United Kingdom 32 (1.4)
 Greece 30 (1.4)
 Slovakia 26 (1.2)
 Norway 24 (1.1)
 Sweden 23 (1.0)
 Romania 21 (0.9)
 Latvia 18 (0.8)
 Estonia 12 (0.5)
 Lithuania 11 (0.5)
 Slovenia 8 (0.4)
 Czech Republic 7 (0.3)
 Denmark 4 (0.2)
Outside Europe
 China 252 (11.4)
 Taiwan 140 (6.3)
 Australia 101 (4.6)
 Japan 98 (4.4)
 Turkey 91 (4.1)
 Russia 60 (2.7)
 Israel 59 (2.7)
 Thailand 50 (2.3)
 South Africa 31 (1.4)
 Korea 20 (0.9)
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3.3 | Treatment
At baseline, a total of 1226 patients (98.1%) with focal sei-
zures in the overall epilepsy cohort received treatment. 
The majority received GABAergics as a single agent or in 
combination with other treatment modalities (803, 65.5%). 
Additional treatment modalities included mTOR inhibitors 
(95, 7.7%), surgery (85, 6.9%), ketogenic diet (58, 4.7%), 
vagus nerve stimulation (47, 3.8%), fructose derivatives (43, 
3.5%), and corticotropin (ACTH; 35, 2.9%). Focal seizures 
were controlled by treatment in 713 patients (58.2%), re-
solved spontaneously in 9 (0.7%), and were not controlled in 
466 patients (38%). Outcome data were not available for 38 
patients (3.1%).
A total of 696 patients (96.7%) in the overall epilepsy co-
hort received treatment for infantile spasms. The most fre-
quent treatment modalities (as single agents or in combination 
with other treatment modalities) included GABAergics (548, 
78.7%) and ACTH (122, 17.5%). Additional treatment mo-
dalities included mTOR inhibitors (38, 5.5%), surgery (29, 
4.2%), ketogenic diet (27, 3.9%), vagus nerve stimulator (15, 
2.2%), and fructose derivatives (9, 1.3%). Infantile spasms 
were controlled with treatment in 530 (76.3%), resolved 
spontaneously in 23 (3.3%), and were not controlled in 108 
patients (15.5%). Outcome data were not available for 34 pa-
tients (4.9%). The type of treatment and overall outcome of 
focal seizures and infantile spasms in the patients diagnosed 
with epilepsy before the age of 2 years (early onset seizure 
group) were similar to those in the overall epilepsy cohort 
(Table 3). Type of treatment and overall outcome of focal sei-
zures and infantile spasms in relation to mutation type are 
shown in Table 4.
3.4 | Association between seizure 
control and intellectual ability
In the overall epilepsy cohort, a total of 563 of 1250 patients 
with focal seizures reported at baseline (45%) had received 
an evaluation of their intellectual abilities assessed by the cli-
nician or by standardized tests depending on the local best 
practice. Of these, 229 patients (40.7%) had normal intellec-
tual ability, whereas the degree of intellectual disability was 
recorded as mild in 178 (31.6%), moderate in 58 (10.3%), 
severe in 86 (15.3%), and profound in 12 patients (2.1%). Of 
720 patients in the overall epilepsy cohort with a history of 
infantile spasms, 279 patients (38.8%) had been evaluated by 
formal tests for IQ. Of these, 61 patients (21.9%) had nor-
mal intellectual ability, whereas mild, moderate, severe, and 
profound degrees of intellectual disability were observed in 
82 (29.4%), 73 (26.2%), 46 (16.5%) and 17 patients (6.1%), 
respectively. The proportion of patients with normal intellec-
tual ability was higher in patients controlled with treatment 
than in those not controlled with treatment (23.5% vs 7.9%, 
patients with infantile spasms, and 47.5% vs 26.8%, patients 
with focal seizures; Figure 1).
In the early onset seizure group, 459 of 984 patients 
(46.6%) diagnosed with focal seizures had been evaluated for 
IQ. Of these, 158 patients (34.4%) had normal intellectual 
ability, whereas mild, moderate, severe, and profound degrees 
T A B L E  2  Baseline patient demographics and clinical 
characteristics (N = 2216)
Characteristics Baseline data
Age at diagnosis of TSCa, years, median (range) 1 (<1- 69)
Gender, n (%)
 Male 1062 (47.9)
 Female 1154 (52.1)
Patients with molecular testing, n (%) 1000 (45.1%)
Genetic testing, n (%)b
 No mutation identified 144 (14.4)
 TSC1 mutationc 197 (19.7)
 TSC2 mutationc 644 (64.4)
Variation type, n (%)d
 Pathogenic mutation 678 (67.8)
 Variant of unknown significance 66 (6.6)
Time from first TSC clinical diagnosis to first molecular testing, 
months
 Mean (SD) 80.8 (116.5)
 Median (range) 23 (<1- 721)
Patients with prenatal diagnosis, n (%) 144 (6.5)
Biologic mother/father evaluated for TSC, n
 Mother 936
 Father 820
TSC inherited from one parent, n
 Total 51
 Mother 30
 Father 21
Patients with affected relatives, n (%)e
 Total 500 (22.6)
 1 275 (12.4)
 2 138 (6.2)
 3 50 (2.3)
 >3 54 (2.4)
Patients with at least one blood relative 
participating in TOSCA, n (%)
230 (10.4)
SD, standard deviation; TSC, tuberous sclerosis complex; TOSCA, TuberOus 
SClerosis registry to increase disease Awareness.
aData available for 2179 patients. 
bInformation on the type of mutation was missing for 9 patients. 
cThe count (n) includes 6 patients who had both TSC1 and TSC2 mutations. 
dThe count (n) includes 23 patients who had both variation types. 
ePatients switching from one category to the other during the study visits were 
counted in each category. 
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of intellectual disability were observed in 151 (32.9%), 81 
(17.6%), 57 (12.4%), and 12 (2.6%) patients, respectively. 
Among the 684 patients diagnosed with infantile spasms in 
the early onset seizure group, 273 (39.9%) were evaluated 
for IQ. A total of 59 patients (21.6%) had normal intellec-
tual ability, whereas mild, moderate, severe, and profound 
degrees of intellectual disability was observed in 82 (30%), 
71 (26%), 44 (16.1%), and 17 (6.2%) patients, respectively. 
Similar to the overall epilepsy cohort, the proportion of pa-
tients with normal intellectual ability was higher in the early 
onset seizure group that had been controlled than the group 
with uncontrolled focal seizure (41.2% vs 21.4%) and infan-
tile spasms (23.3% vs 7.9%) after treatment.
4 |  DISCUSSION
The TOSCA study, which represents the largest cohort of pa-
tients with TSC described to date, enrolled patients from 31 
countries and from various specialty clinics. The third interim 
analysis results showed an occurrence at baseline of epilepsy 
in about 83.6% of the of 2216 enrolled patients, which was in 
line with both the baseline “core” data of the TOSCA regis-
try10 and other previous reports,1,8,13 confirming epilepsy to 
be the most common clinical presentation of TSC.
A database of 1816 individuals with TSC showed that 
focal seizures were present in 81.8% of the patients and infan-
tile spasms in 49.2% of the patients included.2 In agreement 
with this report, focal seizures were also the most common 
seizure observed in our cohort, followed by infantile spasms. 
A history of infantile spasms was reported in about 38.9% 
T A B L E  3  Type of epilepsy and treatment outcomes in overall 
epilepsy cohort and in patients diagnosed at <2 years at baseline
Characteristics
Overall epilepsy 
cohort (N = 1852),  
n (%)
Early onset seizure 
group, (N = 1461), 
n (%)
Epilepsy type
 Focal seizuresa 1250 (67.5) 984 (67.4)
 Infantile 
spasmsa
720 (38.9) 684 (46.8)
 Focal seizures 
only
765 (41.3) 530 (36.3)
 Infantile 
spasms only
246 (13.3) 221 (15.1)
 Co- occurrence 
of infantile 
spasms and 
focal seizures
380 (20.5) 375 (25.7)
Treatmentb for infantile spasm
No. of patients 
who received 
treatment
696 (96.7) 663 (96.9)
Type of treatment
 GABAergics 548 (78.7) 527 (79.5)
 ACTH 122 (17.5) 121 (18.3)
 mTOR 
inhibitors
38 (5.5) - 
 Surgery 29 (4.2) - 
 Ketogenic diet 27 (3.9) - 
 Vagus nerve 
stimulator
15 (2.2) - 
 Fructose 
derivatives
9 (1.3) - 
Treatment outcomes for infantile spasm
 Resolved 
spontaneously
23 (3.3) 34 (5.0)
 Controlled 
with treatment
530 (76.3) 506 (74.5)
 Not controlled 
with treatment
108 (15.5) 106 (15.6)
 Unknown 34 (4 9) 33 (4.9)
Treatmentb for focal seizures
No. of patients 
who received 
treatment
1226 (98.1) 969 (98.5)
Type of treatment
 GABAergics 803 (65.5) 683 (70.5)
 mTOR 
inhibitors
95 (7.7) - 
 Surgery 85 (6.9) - 
 Ketogenic diet 58 (4.7) - 
Characteristics
Overall epilepsy 
cohort (N = 1852),  
n (%)
Early onset seizure 
group, (N = 1461), 
n (%)
 Vagus nerve 
stimulator
47 (3.8) - 
 Fructose 
derivatives
43 (3.5) - 
 ACTH 35 (2.9) 32 (3.3)
Treatment outcomes for focal seizures
 Resolved 
spontaneously
9 (0.7) 10 (1.0)
 Controlled 
with treatment
713 (58.2) 552 (56.6)
 Not controlled 
with treatment
466 (38.0) 384 (39.3)
 Unknown 38 (3.1) 30 (3.1)
ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin.
aAlone or with other seizures. 
bAs single therapy and in combination with other modalities. 
(Continues)
T A B L E  3  (Continued)
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T A B L E  4  Characteristics of epilepsy according to mutation type
Characteristics
Overall epilepsy cohort with molecular testing
Early onset seizure group with molecular 
testing
TSC1 mutation 
(N = 152), n (%)
TSC2 mutation 
(N = 569), n (%)
TSC1 mutation 
(N = 98), n (%)
TSC2 mutation 
(N = 489), n (%)
Epilepsy type
 Focal seizuresa 113 (74.3) 409 (71.9) 75 (76.5) 350 (71.6)
 Infantile spasmsa 35 (23) 269 (47.3) 34 (34.7) 260 (53.2)
 Infantile spasms only 12 (7.9) 67 (11.8) 11 (11.2) 61 (12.5)
 Focal seizures only 88 (57.9) 220 (38.7) 52 (53.1) 168 (34.4)
 Concomitant infantile spasms 
and focal seizures
21 (13.8) 163 (28.6) 21 (21.4) 161 (32.9)
Age at diagnosis, years
 Focal seizures
 Mean 3.7 2.2 1.1 0.9
 Median 2.0 <1 1 <1
 Range <1- 47 <1- 59 <1- 14 <1- 16
 Infantile Spasms
 Mean 0.3 0.3 0.3 0.2
 Median <1 <1 <1 <1
 Range <1- 6 <1- 5 <1- 6 <1- 4
Treatmentb for infantile spasm
No. of patients who received treatment 33 (94.3) 264 (98.1) 32 (94.1) 256 (98.5)
Type of treatment
 GABAergics 22 (66.7) 223 (84.5) 22 (68.8) 216 (84.4)
 ACTH 4 (12.1) 43 (16.3) 4 (12.5) 40 (15.6)
 Surgery 2 (6.1) 15 (5.7) - - 
 mTOR inhibitors 2 (6.1) 16 (6.1) - - 
 Vagus nerve stimulator 1 (3) 9 (3.4) - - 
 Fructose derivatives 0 2 (0.8) - - 
 Ketogenic diet 0 14 (5.3) - - 
Treatment outcomes for infantile spasm
 Resolved spontaneously 1 (3) 6 (2.3) 3 (8.8) 9 (3.5)
 Controlled with treatment 21 (63.6) 206 (78) 20 (58.8) 199 (76.8)
 Not controlled with treatment 10 (30.3) 40 (15.2) 10 (29.4) 40 (15.4)
 Unknown 1 (3) 12 (4.5) 1 (2.9) 11 (4.2)
Treatmentb for focal seizures
No. of patients who received 
treatment
113 (100) 402 (98.3) 75 (100) 348 (99.4)
Type of treatment
 GABAergics 67 (59.3) 316 (78.6) 51(68) 280 (80.5)
 ACTH 2 (1.8) 7 (1.7) 2 (2.7) 7 (2.0)
 Surgery 8 (7.1) 37 (9.2) - - 
 mTOR inhibitors 6 (5.3) 34 (8.5) - - 
(Continues)
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patients with TSC in the TOSCA study, which was similar 
to that observed in a single center clinical case series of 291 
patients by Chu- Shore et al1, which reported infantile spasms 
in approximately 37% of patients with TSC. However, Jeong 
et al.2 reported a slightly higher rate of infantile spasms 
(about 49.2%). This could be because patients with TSC in 
the series of Jeong et al were self- enrolled by families that 
might have biased recruitment to more severe cases.
It has been reported that epilepsies associated with TSC 
most often have their onset during infancy or early childhood, 
although they may occur at any age, with focal seizures and 
infantile spasms being the most common seizure types.5,14 
In our study, epilepsy was diagnosed before 2 years of age 
in about 79% of patients, showing this early onset in the ma-
jority of patients. However, seizure onset occurred later in 
27% of the cohort, and even in patients older than 40 years 
of age (about 7 patients [0.6%] diagnosed with focal seizures 
at age >40 years). This emphasizes that patients with TSC 
remain at increased risk of epilepsy (mainly focal epilepsies) 
throughout their lifetime. The occurrence of infantile spasms 
was higher in the first 2 years (46.8% vs 38.9%), but the oc-
currence rate of focal seizures was similar (67.4% vs 67.5%) 
between the whole cohort and the early onset seizure group, 
respectively. Late- onset epileptic spasms occurred in 2%- 6% 
of patients.15 This late occurrence of epileptic spasms was 
reported in structural epilepsies without specifying TSC.15,16 
Our data suggest that TSC can be considered as a cause of 
late- onset epileptic spasms. These findings mainly highlight 
that infantile spasms and focal seizures occur at an early age 
in the majority of patients with TSC. Infantile spasms can 
precede, co- occur, or follow focal seizures, with this co- 
occurrence being a characteristic of TSC.17
This emphasizes the importance of parental education and 
the potential role of serial electroencephalography (EEG) 
recordings to detect possible subclinical seizures. This has 
been suggested in patients with antenatal diagnosis of TSC 
or patients diagnosed with TSC before the onset of clinical 
seizures The question on the usefulness to initiate the treat-
ment for subclinical seizures (seizures on EEG without clini-
cal manifestations), or even paroxysmal EEG activity without 
subclinical seizures, is still under debate.18,19 Two projects 
(EPISTOP20 and PREVENT21) are ongoing with the aim of 
evaluating the impact of an early presymptomatic treatment 
to be administered at identification of EEG abnormalities 
without any clinical seizures reported or recorded in patients 
with TSC.
With respect to genotype, infantile spasms were more fre-
quently seen in patients with a TSC2 mutation compared to 
those with a TSC1 mutation (47.3% vs 23%). Furthermore, 
patients with a TSC2 mutation had an earlier onset of in-
fantile spasms and focal seizures (Table 4). These findings 
reinforced the observations seen in previous studies eval-
uating the genotype- phenotype relationships in patients 
with TSC,1,22and could suggest a better efficacy of earlier 
treatments.
GABAergic drugs were the most frequent therapy used 
in patients with focal seizures and patients with infantile 
spasms. The term GABAergic drugs was used for vigabatrin 
and did not include other GABAergic drugs. This finding 
is in line with the current recommendations that vigabatrin 
should be used as a first- line AED treatment for infantile 
spasms with TSC and for focal seizures occurring before the 
age of 1 year.5,23 A better outcome with vigabatrin initiation 
in association with hormonal therapy was reported in a co-
hort of patients with infantile spasms.24 However, patients 
with TSC were excluded from this study and the potential 
additional benefit from this inaugural bi- therapy might need 
additional investigation. The number of patients resistant to 
Characteristics
Overall epilepsy cohort with molecular testing
Early onset seizure group with molecular 
testing
TSC1 mutation 
(N = 152), n (%)
TSC2 mutation 
(N = 569), n (%)
TSC1 mutation 
(N = 98), n (%)
TSC2 mutation 
(N = 489), n (%)
 Vagus nerve stimulator 4 (3.5) 16 (4) - - 
 Fructose derivatives 6 (5.3) 14 (3.5) - - 
 Ketogenic diet 2 (1.8) 33 (8.2) - - 
Treatment outcomes for focal seizures
 Resolved spontaneously 0 3 (0.7) 0 4 (1.1)
 Controlled with treatment 67(59.3) 229 (57.0) 44 (58.7) 195 (55.9)
 Not controlled with treatment 42 (37.2) 163 (40.5) 30 (40) 145 (41.5)
 Unknown 4 (3.5) 7 (1.7) 1 (1.3) 5 (1.4)
ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin.
aAlone or with other seizures. 
bAs single therapy and in combination. 
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treatment was higher for focal seizure (38%) than for infantile 
spasms (15.5%) and was independent of the mutation type. 
This emphasizes the better control of infantile spasms with 
a less efficacy on focal seizures control as they might persist 
or newly occur after the control of spasms. This finding is 
important for the development of new therapies for epilepsy 
in TSC, especially for focal seizures that were not controlled 
as well by available treatments. The recent EXIST 3 study 
showing higher efficacy of adjunctive everolimus therapy in 
patients with treatment- refractory seizures associated with 
TSC compared to placebo, is promising in this regard.25
The number of patients not controlled on treatment at base-
line was much lower in our study (infantile spasms, 15.5%; 
focal seizures; 38%) than the 62.5% reported in a previous 
study by Chu- Shore et al.1 This lower number of treatment- 
resistant patients could be explained by the earlier diagnosis 
age shown by the high number of young patients enrolled in 
our study and by the fact that patients were diagnosed and 
managed in specialized reference centers that follow estab-
lished recommended guidelines.23 There has been substantial 
progress in understanding of diagnosis and treatment of ep-
ilepsy in patients with TSC during the last decade. The rec-
ommendations of serial EEG studies before clinical seizures 
have allowed the detection of some patients with subtle or 
infraclinical seizures. In addition, current recommendation 
on the use of vigabatrin for both infantile spasms and focal 
seizures for infants might have contributed to this lower rate 
of pharmacoresistance.5,23
Studies exploring the efficacy of the ketogenic diet and vagus 
nerve stimulation in patients with TSC- associated epilepsy 
showed that these nonpharmacologic therapies were effective in 
reducing seizure frequency.26–29 Surprisingly, the ketogenic diet 
and vagus nerve stimulation were not commonly used in this co-
hort with a large proportion of patients with pharmacoresistant 
epilepsy. This cannot be totally due to lack of availability of such 
therapies, as many of the TOSCA sites were tertiary centers for 
TSC and epilepsy treatment. Some explanation can emerge ex-
plaining this lower use, as vagus nerve stimulation devices create 
difficulties for routine use of magnetic resonance imaging (MRI) 
of the brain or kidney, and the ketogenic diet is more difficult to 
achieve in patients with psychiatric and behavior disorders that are 
frequent in the patients with TSC presenting epilepsy. In addition, 
many of the severely delayed patients can be in specialized insti-
tutions where the ketogenic diet is not available. The number of 
patients that underwent epilepsy surgery was also relatively low 
in this cohort. Epilepsy surgery for patients with TSC needs spe-
cific expertise, as there is often more than a single tuber focus and 
surgery may need invasive monitoring of seizures to determine 
F I G U R E  1  Effect of seizure control 
on intellectual ability. A, Patients with focal 
seizures. B, Patients with infantile spasms
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the resection area.30,31 This might be the main limiting factor for 
epilepsy surgery but should be a reminder to refer patients with 
pharmacoresistant epilepsy early on to expert epilepsy surgery 
centers to define the possibility of such therapy that is showing 
fair results, even in patients with multiple foci.32
The correlation between intellectual ability and seizure con-
trol in TSC has been reported.33–37 Patients with uncontrolled 
seizures had a higher rate of intellectual disability compared to 
those with controlled seizures. This association is known primar-
ily for infantile spasms,33–37but our cohort showed that pharma-
coresistant focal seizures equally impact intellectual development 
in patients with TSC. Similar to these findings, the present study 
showed that a smaller proportion of patients who were controlled 
with treatment had intellectual disability compared to those un-
controlled in both groups of infantile spasms and focal seizures.
We acknowledge selection bias as one of the limitations of 
our study, given that recruitment was achieved through clinical 
centers with expertise in TSC. Milder cases, or those without 
seizure disorders in childhood, may not have been included. This 
study was recruited mainly from pediatric and adult centers for 
TSC dedicated to epilepsy care, but with almost 30% of patients 
(mainly adult) enrolled from other specialties as well. Despite 
the involvement of several specialty clinics, the rate of epilepsy 
observed in our study was very high (>80%). Furthermore, due 
to the observational nature of the registry, only data collected 
from routine clinical practice were reported. This may in part 
explain the incomplete genetic and neuropsychological scores 
data, given the widespread differences in access to clinical eval-
uation of patients with TSC across the globe even in specialized 
centers, and the lack of access to neuropsychological evaluation. 
Nevertheless, participation of a large number of centers (170 
sites in 31 countries) with complementary expertise has helped 
in the inclusion of a significant number of patients with TSC, 
which is likely to be representative of tertiary hospital clinical 
practice. The lower number of unknown data for epilepsy in 
this registry with a very large cohort reflects good quality data 
collection. Moreover, medical data reported in the registry were 
collected directly by the patients’ physician and not provided by 
patients and families, ensuring a high level of medical accuracy. 
Finally, therapies were recorded in groups of AEDs, as the pur-
pose of this registry was to increase disease awareness and to 
report epilepsy characteristics, and not to evaluate the efficacy 
of specific therapies.
In conclusion, TOSCA provides valuable insights into the 
characteristics of epilepsy in patients with TSC. Our aim was 
to increase awareness on the disease and to present a picture 
of patients’ characteristics and interventions in a very large 
number of centers dedicated for TSC care around the world. 
The findings in this study support previous studies highlight-
ing the higher prevalence of epilepsy in patients with TSC 
with onset during infancy or early childhood, the correla-
tion between seizure control and intellectual outcome, and 
the ongoing need for therapies for both infantile spasms and 
focal seizures as well as for even closer developmental ob-
servations correlated with these. The findings also emphasize 
the better seizure control compared to previous studies that 
might be multifactorial encompassing earlier diagnosis and a 
widespread use of the international guidelines for therapies. 
However, standardized neuropsychological and psychiatric 
assessment is still lacking in many countries, even in ref-
erence centers, and this should be better addressed and im-
plemented.10,38 Finally, the surgery as a rare recourse in the 
therapy arsenal should be further investigated and a closer 
interaction with expert centers for epilepsy surgery should be 
encouraged.
Further analysis of collected data of the TOSCA study 
will provide more details in understanding the treatment 
interventions and outcomes and might inform on the devel-
opment of our knowledge on a rare disease exploring time- 
related changes through these data regarding different aspects 
as age of diagnosis, therapies, and therapy responses.
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